As weight loss leaders boom, one biotech contender abandons its quest with Chapter 7 liquidation

Weight loss drugs were her­ald­ed as one of the biggest in­no­va­tions in bio­phar­ma in 2023, as the GLP-1 con­tenders swelled in­to megablock­busters. But for one small biotech look­ing to make it big in the busi­ness of shed­ding pounds, this year marks the end of the line on a long and wind­ing trail that led to biotech Boot Hill.

Gele­sis, which was backed by PureTech, qui­et­ly filed for Chap­ter 7 bank­rupt­cy liq­ui­da­tion mid-week, weeks af­ter PureTech gave up on a plan to bring the strug­gling out­fit back in­to the fold. PureTech is led by Daphne Zo­har, who is mar­ried to Gele­sis founder and CEO Yishai Zo­har, though a spokesper­son tells End­points News that she re­cused her­self from any of the de­ci­sion-mak­ing re­gard­ing Gele­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Pharma companies soften tone on full IRA impact

De­spite the phar­ma­ceu­ti­cal in­dus­try’s heavy crit­i­cism of the In­fla­tion Re­duc­tion Act, John­son & John­son, Pfiz­er and Bris­tol My­ers Squibb re­cent­ly down­played the leg­is­la­tion’s over­all im­pact

Read More »